First National Bank & Trust Co. of Newtown Trims Stake in Eli Lilly and Company $LLY

First National Bank & Trust Co. of Newtown cut its holdings in Eli Lilly and Company (NYSE:LLY) by 24.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,453 shares of the company’s stock after selling 787 shares during the period. First National Bank & Trust Co. of Newtown’s holdings in Eli Lilly and Company were worth $2,256,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Spire Wealth Management lifted its stake in Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares in the last quarter. Coldstream Capital Management Inc. grew its position in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after purchasing an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares in the last quarter. Iams Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $754,000. Finally, Militia Capital Partners LP increased its holdings in shares of Eli Lilly and Company by 333.3% in the third quarter. Militia Capital Partners LP now owns 2,600 shares of the company’s stock worth $1,984,000 after purchasing an additional 2,000 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,215.41 on Friday. The firm has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 43.18, a PEG ratio of 1.51 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The business has a 50 day simple moving average of $1,091.91 and a 200-day simple moving average of $1,032.43. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the company posted $3.34 EPS. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.81 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Record use of GLP-1 drugs in the U.S. is supporting Eli Lilly’s best-selling obesity treatment business, with sales momentum accelerating for the company’s leading drug franchise. Record Numbers of Americans Are on GLP-1 Drugs. That’s Great News for This Stock.
• Positive Sentiment: Royal Bank of Canada raised its price target on LLY to $1,500 and kept an outperform rating, reinforcing Wall Street’s bullish view on Lilly’s growth outlook and drug demand. Eli Lilly and Company (NYSE:LLY) Given New $1,500.00 Price Target at Royal Bank Of Canada
• Positive Sentiment: Lilly announced new Alzheimer’s disease research presentations for AAIC 2026, including data on Kisunla and P-tau217 blood tests, highlighting a broader pipeline beyond weight-loss drugs. Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
• Positive Sentiment: Canadian regulators gave a positive recommendation for Lilly’s eczema treatment, adding another potential growth driver outside obesity and diabetes. Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada
• Neutral Sentiment: Tampa General Hospital sued Eli Lilly over alleged removal of 340B discounts, creating a legal and pricing overhang, though the financial impact is still uncertain. Tampa General sues Eli Lilly for allegedly pulling 340B discounts

Analysts Set New Price Targets

A number of equities analysts recently commented on LLY shares. Rothschild & Co Redburn increased their price target on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a report on Monday. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a report on Friday, May 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,260.33.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.